Novel Antibody-Drug Conjugates Show Encouraging Activity in TNBC
March 7th 2020Novel antibody-drug conjugates have demonstrated high response rates in patients with heavily pretreated metastatic breast cancer, and ongoing studies targeting actionable cell-surface markers may further expand their clinical utility, according to Aditya Bardia, MD, MPH.
All Stakeholders Are Responsible for Genetic Testing
March 7th 2020Physicians should “get out there and test early and often,” to align with a potential new paradigm for genetic testing that allows anyone on the treatment team to identify and test individuals, with the specialist ultimately providing risk management, according to Kevin S. Hughes, MD, FACS.
CDK4/6 Inhibitors Reach New Benchmarks in Overall Survival in HR+ Breast Cancer
March 6th 2020The release of new evidence that CDK4/6 inhibition results in survival gains for patients with hormone receptor–positive, HER2-negative metastatic breast cancer marks a new milestone for the therapeutic approach and may help set the stage for expanding use of these agents into earlier clinical settings.
Can We Use Genomic Profiling Data to Influence Locoregional Treatment Decisions in Breast Cancer?
March 6th 2020Given the solid correlation between the risk of locoregional recurrence (LRR) and distant recurrence, several investigators have examined whether genomic assays that predict risk of distant recurrence can also predict risk of LRR.
Experts Say DCIS Requires Focus on Genomics and Microenvironment
Identifying patients with ductal carcinoma in situ who are more likely to develop invasive breast cancer remains a challenge, despite decades of research and the development of stratification methods to predict progression and recurrence.
Bridging the Knowledge Gap Between Biosimilars and Biologics in Breast Cancer
March 11th 2019Since 2006, the European Medicines Agency has granted marketing authorization for more than 40 biosimilars, and, in less than 4 years, the FDA has approved 17, yet the knowledge gap in the understanding of biosimilarity poses a unique challenge to the agents’ assimilation into clinical practice and possible impact on access and cost savings, experts say.
Antibody-Drug Conjugates Make Headway in TNBC
March 10th 2019The development of antibody-drug conjugates represents a promising strategy for patients with metastatic triple-negative breast cancer, with early clinical trial results suggesting that novel agents could eventually change the landscape for this patient population.
Awareness Critical for Identifying irAEs Early in Breast Cancer
March 10th 2019With tremendous advances and the accelerated approval of atezolizumab plus nab-paclitaxel for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer, provider education in identifying associated toxicities from checkpoint inhibitor therapy is critical.
Dr. Tripathy on Combination Strategies With CDK4/6 Inhibitors in Breast Cancer
March 9th 2019Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses combination strategies being investigated with CDK4/6 inhibitors in breast cancer.
Promising Debut for PARP Inhibitors Spurs Excitement for Future Therapy
March 9th 2019The introduction of PARP inhibitors into the breast cancer treatment paradigm is a clinically meaningful advance for patients with germline BRCA1/2 mutations but much more research must be conducted to optimize their use.
Addition of Alpelisib Prolongs PFS in PIK3CA-Mutant HR+, HER2- Advanced Breast Cancer Subgroups
March 9th 2019The previously demonstrated progression-free survival benefit from the addition of alpelisib to fulvestrant appeared consistent among subgroups of patients with hormone receptor–positive/HER2-negative advanced breast cancer who have a PIK3CA mutation.
Treatment Tailoring Possible With Gene Expression Profiling
Each gene expression-based test available for risk prediction in patients with breast cancer has unique properties and they are not interchangeable, placing importance on the clinical studies used to validate the clinical utility of each assay.
Dr. Mittendorf on FDA Approval of Frontline Atezolizumab/Nab-Paclitaxel in PD-L1+ TNBC
March 9th 2019Elizabeth A. Mittendorf, MD, PhD, director of the Breast Immuno-Oncology Program at Dana-Farber/Brigham and Women's Cancer Center, discusses the frontline approval of atezolizumab in combination with nab-paclitaxel in patients with locally advanced or metastatic PD-L1